Glucose Intravenous Infusion B.P. Bieffe

Glucose Intravenous Infusion B.P. Bieffe is an intravenous solution that contains glucose monohydrate as its sole active ingredient. It is supplied as a sterile, aqueous infusion intended for parenteral administration. The product is manufactured in the European Union and is available by prescription. It provides a direct source of glucose for patients who require intravenous energy supplementation, such as during surgery, critical illness, or treatment of hypoglycemia.

Glucose Intravenous Infusion B.P. Bieffe is used when rapid delivery of glucose is needed to maintain blood sugar levels or to supply energy in clinical settings. It is commonly employed in hospitals for patients who cannot receive nutrition orally or enterally.

- Management of acute hypoglycemia in patients unable to take oral glucose. - Energy supplementation during surgical procedures or anesthesia. - Support for patients with critical illness who require parenteral nutrition. - Maintenance of blood glucose concentrations in patients receiving intensive care. - Provision of carbohydrate calories in total parenteral nutrition regimens.

Intravenous glucose can be associated with a range of adverse reactions, most of which are related to the infusion itself or to rapid changes in blood glucose.

Common: - Local irritation or phlebitis at the infusion site. - Mild hyperglycemia with transient elevation of blood glucose. - Electrolyte shifts, particularly decreased serum potassium. - Nausea or mild gastrointestinal discomfort.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload and pulmonary edema in susceptible patients. - Hypersensitivity reactions, including rash or anaphylaxis. - Hyperosmolar hyperglycemic state in patients with impaired insulin response.

Before initiating Glucose Intravenous Infusion B.P. Bieffe, clinicians should evaluate patient-specific factors and monitor relevant parameters to reduce the risk of complications.

- Assess baseline blood glucose and adjust infusion rate to avoid rapid spikes. - Evaluate fluid status and cardiac function to prevent overload. - Monitor electrolytes, especially potassium and phosphate, during prolonged administration. - Use caution in patients with renal or hepatic impairment. - Avoid use in individuals with known hypersensitivity to glucose solutions. - Consider compatibility with other intravenous medications before co‑administration. - Ensure proper aseptic technique to reduce infection risk.

Glucose solutions may interact with certain medications or clinical conditions, influencing their efficacy or safety when administered concurrently.

Avoid: - Co‑administration with high‑dose insulin without close glucose monitoring. - Simultaneous infusion of potassium chloride solutions, which can cause precipitation. - Use with hypertonic saline solutions that may increase osmolar load excessively.

Use with caution: - Concurrent administration of diuretics, which may alter fluid and electrolyte balance. - Co‑infusion with calcium‑containing solutions; monitor for calcium‑phosphate precipitation. - Patients receiving beta‑blockers, as they may mask signs of hypoglycemia.